Opportunistic PSA testing is not the safe alternative
Wiener klinische Wochenschrift · 04.11.2026
DOI: 10.1007/s00508-026-02845-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Wiener klinische Wochenschrift, online erschienen am 04.11.2026. Verfasst von Shahrokh F Shariat und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Austria has never implemented an organized prostate cancer screening program, yet opportunistic PSA testing has been widespread for more than three decades. This has produced the harms of screening without the safeguards of a program: testing outside appropriate age and life-expectancy windows, repeated testing of low-risk men, unnecessary biopsy, overdiagnosis and overtreatment, while generating little systematic information on quality or outcomes. Randomized evidence shows that organized, repeated screening can reduce prostate cancer mortality substantially, whereas opportunistic testing delivers less benefit with more overdiagnosis. Contemporary risk-adapted pathways further improve the balance of benefit and harm: defined start and stop ages, PSA-based risk stratification, MRI before biopsy, targeted biopsy, and active surveillance can reduce unnecessary biopsies and detection or treatment of indolent disease without compromising detection of clinically significant cancer. Europe has therefore moved toward organized, PSA-based screening with MRI as a follow-up test. Austria is now participating in PRAISE-U Plus and has initiated a national multidisciplinary consensus process involving 65 experts from 22 organizations. The policy question is no longer whether Austrian men are being screened—they are—but whether screening remains unstructured or becomes organized, quality-assured and equitable. The evidence supports the latter: invite the right men, stratify risk, biopsy selectively, treat only clinically relevant disease, and measure outcomes systematically.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at.
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at.
- Austrian Comprehensive Cancer Network, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at.
- Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at.
- Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at.
- Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at.
Zitieren
APA
Shariat, S. F., & Austrian Prostate Cancer Screening Consensus Group (2026). Opportunistic PSA testing is not the safe alternative. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-026-02845-2
Vancouver
Shariat SF, Austrian Prostate Cancer Screening Consensus Group. Opportunistic PSA testing is not the safe alternative. Wiener klinische Wochenschrift. 2026. doi:10.1007/s00508-026-02845-2
BibTeX
@article{Shariat2026,
author = {Shariat, Shahrokh F and Austrian Prostate Cancer Screening Consensus Group, Austrian Prostate Cancer Screening Consensus Group},
title = {Opportunistic PSA testing is not the safe alternative},
journal = {Wiener klinische Wochenschrift},
year = {2026},
doi = {10.1007/s00508-026-02845-2}
}
EUVIMED